利妥昔单抗治疗继发的外阴阴道坏疽性脓皮病。

Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy.

作者信息

Dixit Shreya, Selva-Nayagam Priya, Hamann Ian, Fischer Gayle

机构信息

1Northern Clinical School, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales; 2Royal Adelaide Hospital, Adelaide, South Australia; and 3Mid North Coast Dermatology, Port Macquarie, New South Wales, Australia.

出版信息

J Low Genit Tract Dis. 2015 Jan;19(1):e6-9. doi: 10.1097/LGT.0000000000000043.

DOI:10.1097/LGT.0000000000000043

PMID:24769650

Abstract

Rituximab is being used increasingly for the treatment of B-cell malignancies and nonmalignant conditions. Pyoderma gangrenosum is a rare neutrophilic dermatosis, which can be either idiopathic or associated with underlying systemic inflammatory conditions. We present a series of 4 patients who presented with ulcerative pyoderma gangrenosum in the vulvovaginal area after treatment with rituximab.

摘要

利妥昔单抗越来越多地用于治疗B细胞恶性肿瘤和非恶性疾病。坏疽性脓皮病是一种罕见的嗜中性皮病，可为特发性或与潜在的全身性炎症性疾病相关。我们报告了4例在接受利妥昔单抗治疗后出现外阴阴道溃疡性坏疽性脓皮病的患者。